Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up

Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up

Purpose/Objective(s): The current study reports long-term overall survival (OS) and biochemical freedom from recurrence (BFFR) after stereotactic body radiation therapy (SBRT) for men with intermediate and high-risk prostate cancer in a single community hospital setting with early adoption.Materials...

Full description

Bibliographic Details
Main Authors:	Anthony Ricco, Gabrielle Barbera, Rachelle Lanciano, Jing Feng, Alexandra Hanlon, Alicia Lozano, Michael Good, Stephen Arrigo, John Lamond, Jun Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-09-01
Series:	Frontiers in Oncology
Subjects:	prostate cancer SBRT (stereotactic body radiation therapy) high risk prostate cancer prostate SBRT treatment intermediate risk prostate cancer
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.01505/full

Similar Items

SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines
by: Matthew eBernetich, et al.
Published: (2014-11-01)

The Comparison of Stereotactic Body Radiation Therapy (SBRT) andIntensity Modulated Radiation Therapy (IMRT) for prostate cancer byNCCN risk groups
by: Anthony Ricco, et al.
Published: (2016-08-01)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
by: Ju Andrew W, et al.
Published: (2013-01-01)

SBRT: An opportunity to improve quality of life for oligometastatic prostate cancer?
by: Gregory eAzzam, et al.
Published: (2015-05-01)

Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose Escalation Study
by: D. Nathan W. Kim, et al.
Published: (2014-11-01)

In regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy
by: Hamed Ghaffari, et al.
Published: (2020-08-01)

The Early Result of Whole Pelvic Radiotherapy and Stereotactic Body Radiotherapy Boost for High Risk Localized Prostate Cancer
by: Yu-Wei eLin, et al.
Published: (2014-10-01)

Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
by: Rebecca Levin-Epstein, et al.
Published: (2020-04-01)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
by: Michael Carrasquilla, et al.
Published: (2021-01-01)

Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer
by: Shih-Chang Wang, et al.
Published: (2020-05-01)

Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a Seven Year Study
by: Alan Jay Katz, et al.
Published: (2014-10-01)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
by: Einsley-Marie eJanowski, et al.
Published: (2015-07-01)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
by: Abigail Pepin, et al.
Published: (2020-05-01)

Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database
by: Anthony Ricco, et al.
Published: (2017-08-01)

Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer
by: Charles C. Vu, et al.
Published: (2014-01-01)

Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer
by: Jennifer Ai-Lian Woo, et al.
Published: (2014-05-01)

Clinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate
by: John Austin Vargo, et al.
Published: (2015-12-01)

Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking
by: Raffaella Lucchini, et al.
Published: (2021-09-01)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
by: Nima Aghdam, et al.
Published: (2020-10-01)

Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning
by: Elisha Fredman, et al.
Published: (2021-09-01)

A Phase II Trial of SABR (Stereotactic Ablative Body Radiotherapy) for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life and Disease Control Outcomes with 5-Year Minimum Followup
by: Constantine Anastasios Mantz
Published: (2014-11-01)

Extreme Hypofractionation with SBRT in Localized Prostate Cancer
by: Maria Antonia Gómez-Aparicio, et al.
Published: (2021-08-01)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
by: Gregor Habl, et al.
Published: (2017-05-01)

Improved irritative voiding symptoms three years after stereotactic body radiation therapy for prostate cancer.
by: Zakie eRana, et al.
Published: (2014-10-01)

Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer
by: Onita eBhattasali, et al.
Published: (2013-12-01)

Urethrogram-directed Stereotactic Body Radiation Therapy (SBRT) for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
by: Ima ePaydar, et al.
Published: (2015-09-01)

Multi-institutional Registry for Prostate Cancer Radiosurgery: An Observational Clinical Trial
by: Debra eFreeman, et al.
Published: (2015-01-01)

Online adaptive planning for prostate stereotactic body radiotherapy using a 1.5 Tesla magnetic resonance imaging-guided linear accelerator
by: Jinzhong Yang, et al.
Published: (2021-01-01)

PROCTITIS ONE WEEK AFTER STEREOTACTIC BODY RADIATION THERAPY FOR PROSTATE CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN
by: Ima Paydar, et al.
Published: (2016-07-01)

Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study
by: Ailleres, N., et al.
Published: (2022)

Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial
by: Minsong Cao, et al.
Published: (2021-06-01)

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
by: Luke Nicholls, et al.
Published: (2020-11-01)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
by: Gaëtan Devos, et al.
Published: (2020-08-01)

ROBOTIC RADIOSURGERY AS A TREATMENT OPTION FOR PATIENTS WITH LOCALIZED PROSTATE CANCER
by: I. A. Vazhenin, et al.
Published: (2016-10-01)

Developments in Stereotactic Body Radiotherapy
by: Anoop Haridass
Published: (2018-12-01)

Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
by: Jennifer Ai-Lian Woo, et al.
Published: (2015-03-01)

Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules
by: Donald Blake Fuller, et al.
Published: (2020-06-01)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
by: Nima Aghdam, et al.
Published: (2020-07-01)

Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
by: Jong Jin Oh, et al.
Published: (2021-04-01)

Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
by: Seth R. Blacksburg, et al.
Published: (2020-12-01)